


Preferred COX-2 inhibitors that may be used in the present invention include, but are not limited to:

C1)



5

JTE-522, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide;

C2)

10


5-chloro-3-(4-(methylsulfonyl)phenyl)-2-(methyl-5-pyridinyl)pyridine;

C3)

15

2-(3,5-difluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one;


C4)



20

4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide;


C5)



rofecoxib, 4-(4-(methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone;

5

C6)



4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide;


10

C7)

N-[[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl]propanamide;


15

C8)




4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl]benzenesulfonamide;


C9)



5 C10)




C11)



10 6-[[5-(4-chlorobenzoyl)-1,4-dimethyl-1H-pyrrol-2-yl]methyl]-3(2H)-pyridazinone;

C12)



N-(4-nitro-2-phenoxyphenyl)methanesulfonamide;